B cell strategy to maintain remission in ANCA-associated vasculitides?
Sabine
S
Adler
Peter M
PM
Villiger
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D055953:Microscopic Polyangiitis / Q000188:drug therapy*; D000069283:Rituximab; D020293:Vasculitis, Central Nervous System / Q000188:drug therapy*
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab